

CDK12-IN-4 biochemical

CDK12-IN-4

CATALOG #
AAA228567


PRODUCT SYNONYMS

CDK12-IN-4; CDK12-IN-4 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2651196-69-7
Targets&IC50	CDK12:0.641 uM (IC50), CDK2/CyclinE:20 uM (IC50), CDK9/CyclinT1:20 uM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	CDK12-IN-4 (Example 172) inhibits BRCA1 mRNA expression in MDA-MB-231 cells (IC 50 =0.626 nM) and has no effect on CAL-120 cells[1]. CDK12-IN-4 has antiproliferative activity in MDA-MB-231 cells (IC 50 =0.535 nM) and CAL-120 cells (IC 50 =2.43 nM)[1]. CDK12-IN-4 has a inhibition IC 50 CDK12 high ATP to Degradation DC 50 CDK12 ratio of 581[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
IKK-IN-3, CAS 615528-53-5



Structure
IKK-IN-3, CAS 615528-53-5

ADDITIONAL INFORMATION

Related Product Information for CDK12-IN-4 biochemical	CDK12-IN-4, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC 50 of 0.641 uM at high ATP (2 mM). CDK12-IN-4 has no effect on CDK2/Cyclin E (IC 50 20 uM) and CDK9/Cyclin T1 (IC 50 20 uM) at high ATP (2 mM)(WO2021116178A1).
References	1. Kempson J, et al. Novel tricyclic inhibitors of IkappaB kinase. J Med Chem. 2009;52(7):1994-2005.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

